Research programme: integrin antagonists - sigma-tau

Drug Profile

Research programme: integrin antagonists - sigma-tau

Alternative Names: ST-1646

Latest Information Update: 29 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ronzoni Institute for Chemical and Biochemical Research; sigma-tau SpA; University of Bari; University of Milan
  • Class Cyclic peptides
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 12 Sep 2006 A preclinical study has been added to the Cancer pharmacodynamics section
  • 14 Feb 2002 A preclinical study has been added to the Cancer pharmacodynamcis section
  • 20 Sep 2001 Preclinical development for Solid tumours in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top